文献速递白血病造血干细胞移植与细胞治疗

复发难治性婴儿急性淋巴细胞白血病研究性CAR-T细胞治疗的可行性与良好缓解

Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALL.
PubMed 文献 · Blood Adv · 2025-01-01

该研究报告了2种实验性CD19 CAR-T细胞产品(SCRI-CAR19或SCRI-CAR19x22)用于19例复发难治性婴儿B-ALL患者的经验。19例中18例(94.7%)成功制备CAR-T产品,17例接受治疗者中16例达到无可检测微小残留病的完全缓解;1年无白血病生存率75%,1年总生存率76.5%,中位随访35.8个月。细胞因子释放综合征发生于14/17例(82.4%),仅1例为3级;神经毒性发生于2/17例(11.8%),均为≤2级。

要点

  • 19例复发难治性婴儿B-ALL中18例(94.7%)成功制备CAR-T产品,17例接受治疗。
  • 17例治疗者中16例达到无可检测微小残留病的完全缓解。
  • 1年无白血病生存率75%、总生存率76.5%,中位随访35.8个月。

核心结论

  • 研究性CD19 CAR-T细胞治疗在复发难治性婴儿B-ALL中显示早期临床可行性与良好缓解,但作者认为需要针对婴儿ALL进行更系统的评估。

研究设计与样本

  • 描述2种实验性CD19 CAR-T细胞产品(SCRI-CAR19或SCRI-CAR19x22)用于19例入组3项临床试验的复发难治性婴儿B-ALL患者的经验。
  • 入组时中位年龄22.5个月(范围14.5-40.1个月)。

主要发现

  • 19例中18例(94.7%)成功制备CAR-T细胞产品。
  • 17例(94.1%)接受治疗的患者中16例达到无可检测微小残留病的完全缓解。
  • 1年无白血病生存率为75%,1年总生存率为76.5%,中位随访时间35.8个月(范围1.7-83.6个月)。
  • 细胞因子释放综合征发生于14/17例(82.4%),仅1例为3级。
  • 神经毒性发生于2/17例(11.8%),所有事件均为≤2级。

局限性

  • 作者指出需要针对婴儿ALL进行更系统的评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infants with B-cell acute lymphoblastic leukemia (B-ALL) continue to have significantly worse outcomes compared with older children with B-ALL, and those with relapsed or refractory (R/R) infant ALL have especially dismal outcomes with conventional treatment. CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable success in the treatment of R/R childhood B-ALL, although the majority of reports have been in noninfant patients. Barriers to the successful implementation of CAR T-cell therapy in infant B-ALL include challenges related to apheresis, product manufacturing, and disease-specific considerations such as lineage switch. We describe our experience using 2 experimental CD19 CAR T-cell products, SCRI-CAR19 or SCRI-CAR19x22, for 19 patients with R/R infant B-ALL enrolled in 3 clinical trials. CAR T-cell products were successfully manufactured in 18 of 19 (94.7%) patients, with a median age of 22.5 months at enrollment (range, 14.5-40.1). Of 17 (94.1%) treated patients, 16 achieved a complete remission without detectable minimal residual disease. The 1-year leukemia-free survival was 75%, and 1-year overall survival was 76.5%, with a median follow-up time of 35.8 months (range, 1.7-83.6). Cytokine release syndrome (CRS) occurred in 14 of 17 (82.4%) patients, with only 1 patient experiencing grade 3 CRS. Neurotoxicity occurred in 2 of 17 (11.8%) patients with all events grade ≤2. With the successful early clinical experience of CAR T-cell therapy in this population, more systematic evaluation specific to infant ALL is warranted.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Annesley C, Lamble A, Summers C, et al. Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALL. Blood Adv. 2025. PMID: 39133891. doi:10.1182/bloodadvances.2024012638

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。